Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated MelanomaGeorgina V. Long, John M. Kirkwood, Vanna Chiarion‐Sileni et al.|New England Journal of Medicine|2017Cited by 1.5k
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Caroline Robert, Georgina V. Long et al.|European Journal of Cancer|2017Cited by 171
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paul B. Chapman, Paolo A. Ascierto et al.|European Journal of Cancer|2020Cited by 69
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Georgina V. Long, Axel Hauschild et al.|The Lancet Oncology|2019Cited by 56
LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)Eric Van Cutsem, Ryan B. Corcoran, Chloé E. Atreya et al.|Annals of Oncology|2015Cited by 23